Abstract
Background Even after successful treatment, tuberculosis (TB) survivors experience elevated morbidity and mortality. However, there is limited evidence on how these risks vary over time and according to individual characteristics.
Methods We conducted a retrospective cohort study of individuals diagnosed with TB in Brazil, using national TB notifications and linked mortality records for 2007-2016. For this study population we estimated mortality rate ratios (MRRs) and cumulative mortality by year since TB diagnosis, as compared to general population mortality rates matched on age, sex, year, and state. We identified clinical and sociodemographic factors associated with elevated post-TB mortality, and compared the distribution of causes of death to the general population.
Findings The study sample included 834,594 individuals, with 4.1 million person-years of follow-up. The TB cohort had elevated mortality compared to the general population, particularly in the first year post-diagnosis (MRR 11.28, 95%CI: 11.18–11.37). Post-TB MRRs declined from 3.59 (3.53–3.64) in year 2 to 1.46 (1.34–1.59) in year 10. Cumulative excess mortality was 6.12% (95%CI: 6.07–6.17) after 1 year and 9.90% (9.58–10.24) after 10 years. MRRs were highest for individuals 30-44 years-old at diagnosis. Relapse, loss to follow-up, and co-prevalent conditions like HIV and alcoholism were strongly associated with higher MRRs. Over time, causes of death shifted from TB and HIV to chronic conditions like cardiovascular disease and cancer.
Interpretation Individuals developing TB disease face elevated mortality up to 10 years after diagnosis. These excess risks vary across demographic and clinical characteristics.
Funding NIH.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health (Award Number R01AI146555 to NM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the Harvard T.H. Chan School of Public Health determined that this study is not human subjects research (Protocol Number: IRB23-0844).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
